Reported Company:

Safety Shot

Researcher Company:

Hunterbrook Media

Price at Report Date:

Close Price Day after report date:

0.9386

% Decline Day after Report Date:

% Decline vs Yesterdays Date:

7.6071

Summary

Hunterbrook Media released a detailed report criticizing Safety Shot (NASDAQ:SHOT), a beverage company that claims to significantly reduce blood alcohol levels within 30 minutes. The report casts serious doubts on these claims, citing an unscientific study where Safety Shot showed no measurable impact on alcohol reduction. Additionally, the report highlights severe adverse effects experienced by some consumers, including vomiting and nausea. Legal challenges also plague the company, with lawsuits over misleading advertising and false affiliations. Financially, Safety Shot is struggling, with significant losses reported despite minimal revenue.

Who is Safety Shot?

Safety Shot is a beverage company that claims its product can reduce blood alcohol content by up to half in 30 minutes. The company markets its drink as a way to quickly sober up, potentially targeting drinkers who want to avoid the effects of alcohol.

Key Points from Report

Dubious Efficacy Claims

• Hunterbrook Media’s informal study found no significant reduction in blood alcohol content for those consuming Safety Shot compared to a control group.
• Experts, including Johns Hopkins’ addiction medicine director, question the biological plausibility of Safety Shot’s claims.

Negative Health Impacts

• Some consumers reported severe reactions, including prolonged vomiting and nausea, after consuming Safety Shot.
• The drink contains N-acetyl cysteine, an ingredient known for its unpleasant taste and smell, often associated with rotten eggs.

Legal and Financial Concerns

• The company has faced lawsuits, including one involving a false association with Coachella and another with a short seller, Capybara Research.
• Safety Shot’s 2023 revenue was $200,000, while its losses exceeded $15 million.

Activ8 Finance Analysis

Hunterbrook Media’s report raises significant concerns about Safety Shot’s product efficacy and safety, alongside questionable business practices. Investors should approach with caution given the company’s legal troubles, financial instability, and unproven product claims. While Hunterbrook Capital’s short position reflects its skepticism, the risks outlined should not be ignored.